New hope for Hard-to-Treat sarcomas? early trial launches
NCT ID NCT07602777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called Risvutatug Rezetecan (Ris-Rez) in adolescents and adults with advanced bone or soft tissue sarcomas that have come back or spread and can't be removed by surgery. The goal is to see if the drug can slow cancer growth and how safe it is. About 113 participants will receive Ris-Rez along with a supportive drug (G-CSF) to help manage side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Risvutatug Rezetecan (Ris-Rez), a biologic drug given by infusion, plus G-CSF to support white blood cell counts
What this could lead to
If it works, this could offer a new treatment option for people with advanced sarcomas that have stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 113 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••